This is the place for the latest information about our work here at Glaucoma Research Foundation and for current events in the world of eye health. All breakthroughs and insights are made possible through the dedication of researchers, and through the continued financial support and active involvement of the community.
This is the place for the latest information about our work here at Glaucoma Research Foundation and for current events in the world of eye health. All breakthroughs and insights are made possible through the dedication of researchers, and through the continued financial support and active involvement of the community.
Allergan has announced the approval of DURYSTA™ (bimatoprost implant), the first biodegradable sustained-release implant for the treatment of open-angle glaucoma
For her research project “Eliminate to Protect,” Dr. Dorota Skowronska-Krawczyk from the University of California, San Diego was awarded the 2020 Shaffer Prize for Innovative Glaucoma Research.
Dr. Pickering delivered the Weston Glaucoma Research Lecture, “A New Era for Glaucoma,” in Palo Alto, California on October 22, 2019.
Learn about novel approaches to drug delivery currently being developed with an aim to improve medical therapy for glaucoma patients.
Two new categories of glaucoma medication eye drops have shown to lower eye pressure significantly and compare well to other established medications.
Trinh Green has faced many vision challenges in her life. But that hasn’t discouraged her. Instead, it’s inspired Trinh to become a vision advocate.
This research progress report summarizes progress from the first year of the Catalyst for a Cure Vision Restoration Initiative, launched by Glaucoma Research Foundation in 2019.
If you have side effects from a glaucoma medication, be sure to tell your doctor, who can adjust your treatment plan based on your needs.
A glaucoma specialist shares her words of advice gathered over the years — advice that each patient should know to better take control of their disease.
A glaucoma patient shares his experience with having selective laser trabeculoplasty (SLT) — a laser treatment for open-angle glaucoma that lowers eye pressure.
Glaucoma Research Foundation hosted our first annual Glaucoma Patient Summit in San Francisco on March 16, 2019.
Although lowering eye pressure can help slow or stop glaucoma progression, there are currently no therapies to regenerate lost nerve cells and help patients that have already lost vision.
The Gleams Newsletter includes interviews, personal stories, and current information about glaucoma, new treatments, updates on research findings, and more. You can subscribe to the printed version of Gleams or the electronic version — both are free.
The Gleams Newsletter includes interviews, personal stories, and current information about glaucoma, new treatments, updates on research findings, and more. You can subscribe to the printed version of Gleams or the electronic version — both are free.
FOR EYECARE PROFESSIONALS
FOR EYECARE PROFESSIONALS
Glaucoma Research Foundation • 251 Post Street, Suite 600 • San Francisco, CA 94108 • 415-986-3162
Send us an email
We are a 501c3 tax-exempt national nonprofit. Our tax ID number is 94-2495035. Our EIN number is 94-2495035.
Copyright 2023 all rights reserved.
Print Subscription
We will mail Gleams anywhere in the United States and Canada, but we do not mail internationally. Please sign up for the email edition if you live outside of the US or Canada.
You can unsubscribe at any time. GRF will not share your personal information with any other organizations. Please see our Privacy Policy for further information.
E-mail Subscription
You can unsubscribe at any time. GRF will not share your personal information with any other organizations. Please see our Privacy Policy for further information.
